CT
Celea TherapeuticsClinical-stage biotech developing deupirfenidone, a deuterated pirfenidone-derived drug for idiopathic pulmonary fibrosis, spun out of PureTech Health.
4 Pulse stories
EM
Encore MedicalEncore Medical develops transcatheter septal occlusion devices to repair structural heart defects like patent foramen ovale (PFO).
2 Pulse stories
Total Raised
$180M
Celea TherapeuticsEncore Medical
Last ValuationNot disclosed
Biotech
Sector
Biotech
2025
Founded
2017
Boston, MA
HQ
Eagan, Minnesota
Private
Status
Public (EMI)
Celea Therapeutics investors
RA Capital ManagementLeaps by BayerPureTech Health
Encore Medical investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Celea Therapeutics and Encore Medical.